Peptides explained
Insulin glargine: how it works
Also known as: Lantus is a brand of insulin glargine
Page updated · Sources and editorial approach
How basal insulin glargine works, what Lantus clinical studies measure and where to find UK prescribing information.
Insulin glargine at a glance
What it does biologically
Lantus releases insulin glargine gradually from a subcutaneous deposit, providing a prolonged action profile.
What the evidence shows
UK prescribing information describes clinical comparisons and adverse effects for the authorised Lantus formulation.
What remains uncertain
The active substance name alone cannot establish a product's action profile, concentration or device.
The basics
What is Insulin glargine?
Insulin glargine is an analogue of human insulin. Lantus is a UK prescription medicine containing insulin glargine.
The term basal refers to background insulin activity. Studies of a specific basal insulin have to be read with its formulation and comparator in mind.
Biological action
How does Insulin glargine work?
The Lantus formulation forms microprecipitates after subcutaneous administration. Insulin is released from this deposit, helping explain the prolonged action profile.
Insulin receptor activity lowers blood glucose through effects on glucose uptake and liver glucose output. The timing of these effects is a separate characteristic from the receptor target.
Questions being investigated
What do studies examine?
Fasting glucose
Fasting glucose measurements can help describe background glucose control.
Nighttime hypoglycaemia
Overnight safety outcomes answer a more specific question than average glucose control.
Long-term outcomes
HbA1c and longer-term clinical outcomes require their own follow-up periods and comparisons.
Strength of evidence
How strong is the evidence?
Evidence is separated by level because a cell experiment, an animal model, a human trial and a regulatory decision answer different questions.
| Evidence type | What it tells us |
|---|---|
| Laboratory | The formulation and mechanism of prolonged release are characterised. |
| Animal | Experimental pharmacology and clinical comparisons answer different questions. |
| Human | UK prescribing information summarises controlled clinical studies of the authorised medicine. |
| Regulatory | The UK product information identifies Lantus SoloStar as a prescription medicine. |
Important context
Risks, limitations and unanswered questions
- Products containing insulin glargine can differ in concentration, action profile and device.
- Study findings depend on the patient population, comparator and background care.
Detailed catalogue research
Lantus and insulin glargine: long-acting basal insulin evidence
A UK medicine reference explaining basal insulin, how glargine studies measure outcomes and why insulin formulations differ.
What is insulin glargine and what does basal insulin mean?
Insulin glargine is a modified human insulin analogue. Lantus is a prescription preparation with a prolonged action profile. Basal insulin refers to background insulin coverage. That role is different from the rapid-acting profile of insulin aspart. The relevant action profile comes from the exact preparation and is one reason the two products cannot be substituted by name alone.
How is clinical evidence for insulin glargine assessed?
Prescribing information describes the population, comparator and outcome. HbA1c reflects longer-term glucose control, while fasting glucose and nighttime hypoglycaemia answer more specific questions. A comparison showing a difference in one outcome does not establish a difference in every outcome. Check whether the trial involved type 1 or type 2 diabetes and what other treatments participants received.
Why do the glargine product name and concentration matter?
Medicines containing insulin glargine can differ in concentration and action profile, as well as in the device used to deliver them. The name Lantus refers to a particular authorised product. A brand note is not a verification of the contents of a separately described item. Hypoglycaemia can be serious and any treatment change belongs with the clinician managing the diabetes.
Sources for this research section
Questions answered
Insulin glargine FAQs
How does insulin glargine differ from insulin aspart?
Lantus contains long-acting insulin glargine. NovoRapid contains rapid-acting insulin aspart. The medicines serve different clinical roles.
Does every insulin glargine product act the same way?
Check the official product information. Concentration, action profile and devices can differ between formulations.
Check the sources
Sources and further reading
Follow the original study or official information to check the population, methods and full results. Reviews and sponsor updates are labelled below.
- Lantus SoloStar UK prescribing information ↗Authorised formulation, pharmacology, clinical data and safety information.
- UK Lantus SoloStar patient leaflet ↗Source for the detailed research section.
Educational information, prepared with AI assistance and not independently clinically reviewed. It is not personal medical advice or a treatment recommendation. Read the editorial policy or suggest a correction.